• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nephros Expands into Puerto Rico to Deliver Differentiated Water Filtration Solutions Across Medical and Commercial Sectors

    2/13/26 8:16:35 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care
    Get the next $NEPH alert in real time by email

    SOUTH ORANGE, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced its entry into the Puerto Rican market, targeting high-need applications such as ice machines, drinking fountains, bottle fillers, and sterile processing environments.

    With a proven track record in infection control and water purity, Nephros brings a differentiated approach to water filtration, delivering advanced products with faster service and local-language support in a region long underserved by premium filtration providers.

    Puerto Rico Market

    With increasing focus on public health, waterborne pathogen risk, and infrastructure-driven water quality challenges, Nephros believes its infection-control filtration solutions serve an unmet need I Puerto Rico. Nephros' filtration solutions offer important safeguards to support point-of-use purification for drinking water equipment, plumbing outlets, and instrument processing across key sectors such as healthcare, foodservice, and hospitality. The company estimates that the Puerto Rican market presents a $10 million opportunity across a variety of sectors, with significant unmet needs in waterborne pathogen and contaminant control:

    • Healthcare – $3M
    • Foodservice – $3M
    • Hotels – $1M
    • Other Hospitality – $1M
    • Service Contracts & Replacements – $1M

    "We believe Puerto Rico is a massively underserved market when it comes to reliable, high-quality filtration—particularly for environments where bacteria and harmful contaminants in water can have serious consequences," said Robert Banks, President and CEO of Nephros. "Our entry into Puerto Rico is a natural extension of our core strategy: leveraging best-in-class technology and execution to meet critical water safety needs."

    Local Service, Rapid Fulfillment, Language-Specific Support

    Nephros plans to differentiate itself by offering:

    • Rapid response and fulfillment from a dedicated inventory network
    • On-site installation and scheduled filter replacements
    • Customer support and technical documentation in Spanish
    • Point-of-use filtration for microbial control and regulated drinking water contaminants such as lead and PFAS

    This localized approach ensures compliance, reliability, and ease of use for customers across the island. Nephros' move into Puerto Rico aligns with its broader growth strategy—expanding into adjacent markets beyond traditional patient care to support water safety within hospitality and foodservice. "We're inspired by the momentum, energized by the cultural pride, and ready to serve. This market launch underscores our belief that small, agile companies with the right technology and team can create meaningful impact even in complex, fragmented markets," added Banks.

    About Nephros

    Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within healthcare and commercial markets, offering both proactive and emergency solutions for water management.

    For more information about Nephros, please visit nephros.com.

    Forward-Looking Statements

    This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros' beliefs about the Puerto Rico market, including the size of the market and Nephros' ability to attain market share, the expected benefits of its filtration products and other statements that are not historical facts, including statements that may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros' dependence on third-party manufacturers, distributors and researchers, changes in competitive conditions and regulatory reforms. These and other risks and uncertainties are detailed in Nephros' reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed following such Form 10-K. Nephros does not undertake any responsibility to update the forward-looking statements in this release.

    Investor Relations Contacts:

    Kirin Smith, President

    PCG Advisory, Inc.

    (646) 823-8656

    [email protected]

    Robert Banks, CEO

    Nephros, Inc.

    (201) 343-5202 x110

    [email protected]



    Primary Logo

    Get the next $NEPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPH
    SEC Filings

    View All

    SEC Form 10-K filed by Nephros Inc.

    10-K - NEPHROS INC (0001196298) (Filer)

    3/12/26 4:01:16 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

    8-K - NEPHROS INC (0001196298) (Filer)

    11/26/25 4:15:32 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Nephros Inc.

    10-Q - NEPHROS INC (0001196298) (Filer)

    11/6/25 4:01:11 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    5/30/24 4:35:22 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    5/16/24 4:49:44 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    3/14/24 4:28:20 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley FBR initiated coverage on Nephros with a new price target

    B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50

    1/26/21 6:12:57 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ­­Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results

    Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Financial HighlightsFourth Quarter Ended December 31, 2025. Net revenue was $4.7 million, compared to $3.9 million in the fourth quarter of 2024, up 22%Net income was $62,000, compared to $349,000 during the same period in 2024Adjust

    3/12/26 4:10:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth-quarter financial results on Thursday, March 12, 2026 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    3/5/26 7:04:28 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Expands into Puerto Rico to Deliver Differentiated Water Filtration Solutions Across Medical and Commercial Sectors

    SOUTH ORANGE, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced its entry into the Puerto Rican market, targeting high-need applications such as ice machines, drinking fountains, bottle fillers, and sterile processing environments. With a proven track record in infection control and water purity, Nephros brings a differentiated approach to water filtration, delivering advanced products with faster service and local-language support in a region long underserved by premium filtration providers. Puerto Rico MarketWith increasing focus on public health,

    2/13/26 8:16:35 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Financials

    Live finance-specific insights

    View All

    ­­Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results

    Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Financial HighlightsFourth Quarter Ended December 31, 2025. Net revenue was $4.7 million, compared to $3.9 million in the fourth quarter of 2024, up 22%Net income was $62,000, compared to $349,000 during the same period in 2024Adjust

    3/12/26 4:10:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth-quarter financial results on Thursday, March 12, 2026 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    3/5/26 7:04:28 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    ¬Nephros Schedules Third Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 6, 2025 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    10/30/25 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Nephros Inc.

    4 - NEPHROS INC (0001196298) (Issuer)

    3/18/26 5:23:08 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Krandel Judy

    4 - NEPHROS INC (0001196298) (Issuer)

    3/18/26 4:17:19 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Director Nettis Lisa Marie was granted 1,622 shares (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    11/13/25 5:00:38 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Leadership Updates

    Live Leadership Updates

    View All

    Nephros Hires Judy Krandel as Chief Financial Officer

    SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv

    11/1/23 7:30:00 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Appoints Joe Harris to Its Board of Directors

    SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment

    9/8/22 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    RION Appoints Alisa Lask as Chief Commercial Officer

    - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

    1/14/22 9:00:00 AM ET
    $CLGN
    $NEPH
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $NEPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:15:24 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:13:44 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:11:33 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care